Autolus Therapeutics (AUTL) Operating Leases (2019 - 2026)

Autolus Therapeutics (AUTL) has 7 years of Operating Leases data on file, last reported at $71.4 million in Q4 2025.

• Quarterly Operating Leases rose 35.64% year-over-year to $71.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $71.4 million (up 35.64% YoY) and the FY2025 annual result came in at $71.4 million, up 35.64% from the prior year.
• Operating Leases advanced to $71.4 million in Q4 2025, from $65.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $71.4 million in Q4 2025 to a low of $11.3 million in Q3 2022.
• A 5-year average of $38.7 million and a median of $45.8 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases tumbled 64.93% — and 2023, when it jumped 315.27%.
• Tracing AUTL's Operating Leases over 5 years: stood at $21.0 million in 2021, then advanced by 15.52% to $24.3 million in 2022, then soared by 118.37% to $53.0 million in 2023, then fell by 0.64% to $52.6 million in 2024, then soared by 35.64% to $71.4 million in 2025.
• The last three Operating Leases figures came in at $71.4 million (Q4 2025), $65.8 million (Q3 2025), and $64.5 million (Q2 2025), per Business Quant data.